Avivagen Inc V.VIV.H

Avivagen

[StoneMan45]

For Immediate Release
Avivagen Announces First Purchase Order from Large Integrated Producer in Asia

Ottawa, ON / Business Wire/ April 26, 2021 / – Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances food production and supports immune function, thereby supporting general health and performance, is pleased to announce it has received its first purchase order from a large, integrated livestock producer in Thailand. The customer is a very large, well-known and respected swine and poultry producer in the region. This first purchase order from this customer, while modest in size, comes on the heels of several trials conducted by the customer with sows and piglets over the last nine months, whereby Avivagen’s OxC-beta^TM Livestock consistently outperformed any and all competitive alternatives.
 
“We are very excited about this purchase from a very large and established market leading livestock producer in Thailand,” said Kym Anthony, Avivagen’s CEO.  “It is our belief that this first purchase, similar to our experience with UNAHCO, will lead to a growing rollout over the coming quarters and years by the customer and is likely to influence other producers in the region to adopt our product. The real world evidence of the benefits of our product are leading to more customer wins and growing adoption of our OxC-beta™ Livestock product.”  
 
With annual livestock feed production in 2020 of 21million tonnes Thailand is an important market opportunity for Avivagen, not only due to its size but the fact that Thailand’s largest livestock export market remains the European Union, where AGPs (Antibiotics as Growth Promoters) have been banned since 2010.